4th Annual Chronic Kidney Disease Drug Development Summit (CKD)
Evvnt Promotion / evvnt
Archiv
01.03.2022 - 03.03.2022 Hyatt Regency Boston, 1 Avenue de Lafayette, 02111 Boston, USA
Time: 08:00 - 17:00
Kongressthemen
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
Kongressorganizer (PCO)
Hanson Wade
Hanson Wade
Anmerkungen
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center and more.
Anfragen und Anmeldung:
https://go.evvnt.com/915880-2?pid=4832
Herr Jessica Durston
Allgemeinmedizin
Sprache
Englisch
Englisch
Kongressgebühr
USD 2099.0 - USD 4996.0
USD 2099.0 - USD 4996.0
Teilnehmer erwartet
1000
1000
Veranstalter Kontakt
83 Great Titchfield Street
W1W 6RH London
Großbritannien
83 Great Titchfield Street
W1W 6RH London
Großbritannien
"GOING INTERNATIONAL fördert den Zugang zu Aus-, Fort- und Weiterbildung, unabhängig von sozialen, geographischen und nationalen Grenzen."
